We are live on ! Find out more
1C

1623 Capital Portfolio holdings

AUM $173M
1-Year Est. Return 17.08%
This Fund
S&P 500
This Quarter Est. Return
-15.05%
1 Year Est. Return
+17.08%
3 Year Est. Return
+11.9%
5 Year Est. Return
10 Year Est. Return
AUM
$160M
AUM Growth
-$39.1M
Cap. Flow
-$4.42M
Cap. Flow %
-2.75%
Top 10 Hldgs %
56.77%
Holding
54
New
3
Increased
15
Reduced
2
Closed
7

Top Buys

Rank Stock Value
1
ADSK icon
Autodesk
ADSK
+$1.71M
2
BR icon
Broadridge
BR
+$1.35M
3
CDLX icon
Cardlytics
CDLX
+$833K
4
ETSY icon
Etsy
ETSY
+$749K
5
MA icon
Mastercard
MA
+$585K

Top Sells

Rank Stock Value
1
SBUX icon
Starbucks
SBUX
+$3.73M
2
EQIX icon
Equinix
EQIX
+$966K
3
SPLK
Splunk Inc
SPLK
+$917K
4
TDOC icon
Teladoc Health
TDOC
+$725K
5
TSHA icon
Taysha Gene Therapies
TSHA
+$305K

Sector Composition

Rank Sector Weight
1 Technology 26.48%
2 Financials 16.82%
3 Consumer Discretionary 11.62%
4 Healthcare 11.42%
5 Real Estate 10.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MTCH icon
26
CALL
Match Group
MTCH
$9.19B
$1.25M 0.78%
18,000
ETWO
27
DELISTED
E2open Parent Holdings
ETWO
$916K 0.57%
117,697
SPIR icon
28
Spire Global
SPIR
$444M
$785K 0.49%
84,594
+15,646
+23% +$200K
CDLX icon
29
Cardlytics
CDLX
$21.7M
$727K 0.45%
3,258
+2,487
+323% +$833K
IAS
30
DELISTED
Integral Ad Science
IAS
$578K 0.36%
58,231
EVBG
31
DELISTED
Everbridge, Inc. Common Stock
EVBG
$564K 0.35%
20,230
BMRN icon
32
BioMarin Pharmaceuticals
BMRN
$11.6B
$497K 0.31%
5,994
-2,690
-31% -$214K
RARE icon
33
Ultragenyx Pharmaceutical
RARE
$2.45B
$431K 0.27%
7,231
+3,187
+79% +$196K
FRSH icon
34
Freshworks
FRSH
$3.14B
$419K 0.26%
31,898
VERV
35
DELISTED
Verve Therapeutics
VERV
$413K 0.26%
26,999
+8,158
+43% +$126K
AMPS
36
DELISTED
Altus Power
AMPS
$395K 0.25%
62,619
+23,778
+61% +$159K
DXCM icon
37
DexCom
DXCM
$31.5B
$393K 0.25%
5,272
+1,912
+57% +$174K
NARI
38
DELISTED
Inari Medical, Inc. Common Stock
NARI
$384K 0.24%
5,647
PEN icon
39
Penumbra
PEN
$12.7B
$354K 0.22%
2,843
+480
+20% +$76.2K
SMAR
40
DELISTED
Smartsheet Inc.
SMAR
$352K 0.22%
11,203
+3,246
+41% +$135K
PTCT icon
41
PTC Therapeutics
PTCT
$5.68B
$334K 0.21%
+8,335
New +$292K
PODD icon
42
Insulet
PODD
$11.5B
$318K 0.2%
1,458
MYNA
43
DELISTED
Mynaric AG American Depository Shares
MYNA
$281K 0.18%
41,111
NTLA icon
44
Intellia Therapeutics
NTLA
$1.49B
$213K 0.13%
4,117
HLGN
45
DELISTED
Heliogen, Inc.
HLGN
$209K 0.13%
2,828
+1,277
+82% +$166K
QTRX icon
46
Quanterix
QTRX
$164M
$197K 0.12%
12,198
SES icon
47
SES AI
SES
$203M
$130K 0.08%
+33,193
New +$213K
AMZN icon
48
CALL
Amazon
AMZN
$2.92T
-30,000
Closed -$4.89M
ASAN icon
49
Asana
ASAN
$1.92B
-7,072
Closed -$283K
SBUX icon
50
Starbucks
SBUX
$120B
-41,000
Closed -$3.73M

Similar funds

1623 Capital's Q2 2022 Portfolio in Review

As of Q2 2022, 1623 Capital held 54 positions worth $160M, down 20% from $200M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

1623 Capital's Q2 2022 filing shows 3 new, 15 increased, 2 reduced and 7 closed positions. Its largest new stake was Autodesk: 8,900 shares worth $1.53M. The largest sale was Starbucks, an estimated $3.73M.

By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 26% a quarter earlier, followed by Financials and Consumer Discretionary.

  • 1623 Capital's largest Q2 2022 buy was Autodesk: 8,900 shares worth $1.53M.
  • 1623 Capital added most to Broadridge in Q2 2022, an estimated $1.35M increase.
  • 1623 Capital's biggest Q2 2022 reduction was Equinix, cutting an estimated $966K.
  • 1623 Capital fully exited Starbucks in Q2 2022, selling an estimated $3.73M.
  • 1623 Capital's ten largest holdings make up 57% of its $160M portfolio in Q2 2022.
  • 1623 Capital opened 3 new positions and closed 7 in Q2 2022.
  • 1623 Capital's portfolio value fell 20% quarter-over-quarter to $160M.

Based on 1623 Capital's 13F filing for Q2 2022, filed 12 Aug 2022.